HK1038865A1 - RAS-法呢基轉移酶抑制物與硫丁基醚-7-β-環糊精或2-羥基丙基-β-環糊精的複合物及方法 - Google Patents

RAS-法呢基轉移酶抑制物與硫丁基醚-7-β-環糊精或2-羥基丙基-β-環糊精的複合物及方法

Info

Publication number
HK1038865A1
HK1038865A1 HK02100115.8A HK02100115A HK1038865A1 HK 1038865 A1 HK1038865 A1 HK 1038865A1 HK 02100115 A HK02100115 A HK 02100115A HK 1038865 A1 HK1038865 A1 HK 1038865A1
Authority
HK
Hong Kong
Prior art keywords
cyclodextrin
beta
sulfobutylether
ras
hydroxypropyl
Prior art date
Application number
HK02100115.8A
Other languages
English (en)
Inventor
S Raghavan Krishnaswamy
M Malloy Timothy
A Varia Sailesh
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HK1038865A1 publication Critical patent/HK1038865A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK02100115.8A 1999-01-21 2002-01-08 RAS-法呢基轉移酶抑制物與硫丁基醚-7-β-環糊精或2-羥基丙基-β-環糊精的複合物及方法 HK1038865A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11664799P 1999-01-21 1999-01-21
PCT/US1999/030424 WO2000042849A1 (en) 1999-01-21 1999-12-21 COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD

Publications (1)

Publication Number Publication Date
HK1038865A1 true HK1038865A1 (zh) 2002-04-04

Family

ID=22368422

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100115.8A HK1038865A1 (zh) 1999-01-21 2002-01-08 RAS-法呢基轉移酶抑制物與硫丁基醚-7-β-環糊精或2-羥基丙基-β-環糊精的複合物及方法

Country Status (33)

Country Link
US (1) US6218375B1 (zh)
EP (1) EP1143796A4 (zh)
JP (1) JP2002535253A (zh)
KR (1) KR100708360B1 (zh)
CN (1) CN1219517C (zh)
AR (1) AR022323A1 (zh)
AU (1) AU772204B2 (zh)
BG (1) BG105666A (zh)
BR (1) BR9916566A (zh)
CA (1) CA2359646C (zh)
CO (1) CO5160253A1 (zh)
CZ (1) CZ20012601A3 (zh)
EE (1) EE200100382A (zh)
GE (1) GEP20043214B (zh)
HK (1) HK1038865A1 (zh)
HU (1) HUP0105160A3 (zh)
ID (1) ID30139A (zh)
IL (1) IL144025A (zh)
LT (1) LT4893B (zh)
LV (1) LV12712B (zh)
MY (1) MY119700A (zh)
NO (1) NO20013585L (zh)
NZ (1) NZ511995A (zh)
PE (1) PE20001419A1 (zh)
PL (1) PL195280B1 (zh)
RU (1) RU2230062C2 (zh)
SK (1) SK9602001A3 (zh)
TR (1) TR200102109T2 (zh)
TW (1) TWI232752B (zh)
UA (1) UA67825C2 (zh)
UY (2) UY25986A1 (zh)
WO (1) WO2000042849A1 (zh)
ZA (1) ZA200104416B (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
EP1443936A4 (en) * 2001-11-13 2006-01-11 Bristol Myers Squibb Co PROCESS FOR THE PREPARATION OF 3,7-DISUBSTITUE-2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPINE COMPOUNDS
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20040009972A1 (en) * 2002-06-17 2004-01-15 Ding Charles Z. Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
AU2006299501B2 (en) * 2005-09-30 2012-11-29 Lundbeck Llc Novel parenteral carbamazepine formulation
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
MX2009005368A (es) * 2006-11-21 2009-06-05 Novartis Ag Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.
AR074052A1 (es) 2008-10-22 2010-12-22 Array Biopharma Inc Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa
RU2627460C2 (ru) * 2010-05-26 2017-08-08 Нейрофиксиа Б.В. Составы 2-иминобиотина и их применение
WO2012034038A2 (en) * 2010-09-09 2012-03-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
ES2642843T3 (es) * 2011-10-07 2017-11-20 Pisces Therapeutics Llc Tratamiento de enfermedad maligna y no maligna con antagonistas de Ras
CN105194685A (zh) * 2015-10-15 2015-12-30 重庆大学 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂
PL3389653T3 (pl) 2015-12-16 2024-02-26 Neurophyxia B.V. 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych
RU2751767C2 (ru) 2016-04-04 2021-07-16 Локсо Онколоджи, Инк. Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR102566858B1 (ko) 2016-05-18 2023-08-11 어레이 바이오파마 인크. (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
CA3240887A1 (en) * 2021-12-15 2023-06-22 Luc BURY Pharmaceutical compositions comprising modified beta-cyclodextrins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1067639A (ja) * 1996-08-26 1998-03-10 Shiseido Co Ltd ビタミンe−ビタミンcリン酸ジエステル/シクロデキストリン包接物及び該包接物を配合した皮膚外用剤

Also Published As

Publication number Publication date
ID30139A (id) 2001-11-08
US6218375B1 (en) 2001-04-17
AR022323A1 (es) 2002-09-04
LV12712B (en) 2002-01-20
TWI232752B (en) 2005-05-21
PE20001419A1 (es) 2001-02-21
RU2230062C2 (ru) 2004-06-10
LT2001064A (en) 2001-10-25
CA2359646A1 (en) 2000-07-27
EE200100382A (et) 2002-12-16
CO5160253A1 (es) 2002-05-30
EP1143796A1 (en) 2001-10-17
NO20013585D0 (no) 2001-07-20
ZA200104416B (en) 2002-05-29
AU2374000A (en) 2000-08-07
IL144025A (en) 2004-05-12
CN1333651A (zh) 2002-01-30
NZ511995A (en) 2003-11-28
BG105666A (en) 2002-04-30
GEP20043214B (en) 2004-04-26
MY119700A (en) 2005-06-30
NO20013585L (no) 2001-09-04
UY25986A1 (es) 2000-09-29
IL144025A0 (en) 2002-04-21
PL195280B1 (pl) 2007-08-31
HUP0105160A2 (hu) 2002-05-29
KR20010101611A (ko) 2001-11-14
SK9602001A3 (en) 2002-06-04
PL366338A1 (en) 2005-01-24
JP2002535253A (ja) 2002-10-22
UY25987A1 (es) 2000-09-29
CA2359646C (en) 2008-12-02
CZ20012601A3 (cs) 2002-05-15
HUP0105160A3 (en) 2003-01-28
WO2000042849A1 (en) 2000-07-27
AU772204B2 (en) 2004-04-22
UA67825C2 (uk) 2004-07-15
LV12712A (lv) 2001-09-20
EP1143796A4 (en) 2002-03-20
LT4893B (lt) 2002-02-25
TR200102109T2 (tr) 2001-12-21
KR100708360B1 (ko) 2007-04-17
CN1219517C (zh) 2005-09-21
BR9916566A (pt) 2001-11-13

Similar Documents

Publication Publication Date Title
HK1038865A1 (zh) RAS-法呢基轉移酶抑制物與硫丁基醚-7-β-環糊精或2-羥基丙基-β-環糊精的複合物及方法
GB2374100B (en) Underreamer and method of use
AU4574501A (en) Method of inhibiting stenosis and restenosis
PL339830A1 (en) Highly efficient catalyst and method of obtaining same
IL140328A0 (en) Inhibitors of transcription factor nf-kb
GB9929560D0 (en) Insert and method of manufacture thereof
PL352129A1 (en) Rhodium electrocatalyzer and method of making same
IL146000A0 (en) Ace-2 inhibiting compounds and methods of use thereof
EP1198184A4 (en) TRANSFER METHOD AND ARTICLE
EP1183030A4 (en) PROCESS FOR THE PREPARATION AND ITS USE OF N-DESMETHYLZOPICLONE
GB2348199B (en) Corrosion inhibitor compositions and methods of making them
GB2367103B (en) Connector and method of use of the connector
GB2358756B (en) Method of advertising
PL334333A1 (en) Method of obtaining cyclodextrin
PL337785A1 (en) Lining unit and method of making same
GB9915036D0 (en) Method of imputting text
AU3721000A (en) Corrosion inhibitor and process
EP1209234A4 (en) DECARABAMYLASE STEREOSTRUCTURE AND METHOD OF USE
AU7559600A (en) V type and/or x type spla2 inhibitors
GB2346869B (en) Improved carton and method of construction therefor
GB2357059B (en) Sticker products and methods of manufacture thereof
AU3148500A (en) Scale and corrosion inhibitor
PL332356A1 (en) Biopreparation and method of obtaining same
PL342185A1 (en) Modified psilium and method of obtaining same
PL335391A1 (en) Novel 8beta-hydroxy-1-dehydroandrostendione and method of obtaining same